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Abstract 31 
Background and objectives For many women pregnancy is the first contact with health 32 
services, thus providing an opportunity to identify renal disease. This study compares 33 
aetiologies and long term renal outcomes of biopsy proven renal disease identified during 34 
pregnancy or within one year postpartum, with non-pregnant women.  35 
Design, setting, participants and measurements Native renal biopsies (1997–2012), in 36 
women of childbearing age (16 to <50yrs), from 21 hospitals were studied. The pregnancy-37 
related diagnosis group included those women with abnormal urinalysis / raised creatinine 38 
identified during pregnancy or within one year postpartum. Pregnancy-related and control 39 
biopsies were matched for age and ethnicity (black vs non-black). 40 
Results 173 pregnancy-related biopsies (19 antenatal, 154 post-pregnancy) were identified 41 
and matched with 1000 controls. Focal segmental glomerulosclerosis (FSGS) was more 42 
common in pregnancy-related biopsies (32.4%) than controls (9.7%) (p<0.001) but there 43 
were no differences in Columbia classification. Women with a pregnancy-related diagnosis 44 
were younger (32.1yrs vs 34.2yrs; p=0.004) and more likely to be black (26.0% vs 13.3%; 45 
p<0.001) than controls, although there were no differences in ethnicities in women with 46 
FSGS. The pregnancy-related group (excluding antenatal biopsies) were more likely to have 47 
a decline in CKD-EPI eGFR in the follow-up period than controls (odds ratio 1.67, 95% CI 48 
1.03-2.71, p=0.04), and this decline appeared to be more rapid (-1.33 vs -0.56 ml/min per 49 
1.73m2 per year respectively; p=0.045). However, there were no differences between groups 50 
in those who required RRT or who died.   51 
Conclusions Pregnancy is an opportunity to detect kidney disease.  FSGS is more common 52 
in women who have been pregnant than in controls, and disease identified in pregnancy or 53 
within one year postpartum is more likely to show a subsequent decline in renal function. 54 
Further work is required to determine whether pregnancy initiates, exacerbates or reveals 55 
renal disease.  56 
 57 
 58 
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Introduction 59 
Chronic kidney disease (CKD) is estimated to affect up to 6% of women of child bearing age 60 
in high income countries (1). Frequently, antenatal visits are the first time women are 61 
assessed by health care, thus providing an opportunity to identify CKD.  However, few 62 
studies have investigated the aetiology of renal disease identified during or after pregnancy, 63 
and to our knowledge none have compared with the spectrum of disease in non-pregnant 64 
women.  Improved understanding of renal pathologies identified during pregnancy will inform 65 
decision making about the necessity of biopsy during or after pregnancy. 66 
Pregnancy is a ‘stress test’ for the kidney and may lead to progression of pre-existing 67 
disease. It is possible that less severe disease may be revealed during pregnancy but there 68 
is limited study of natural history of renal disease identified during or after pregnancy to 69 
guide long term prognosis and management of young women with newly diagnosed CKD.   70 
Our aims were to define the aetiologies and long-term outcomes of renal disease identified 71 
during pregnancy or within one-year postpartum, and compare these with non-pregnant 72 
women of child-bearing age. 73 
 74 
Materials and Methods 75 
All renal biopsy reports for women of child-bearing age (16 to <50yrs) from five renal units 76 
serving 21 referring hospitals (1997-2012) were reviewed. The clinical details of the reason 77 
for biopsy were assessed, and pathology records interrogated. Women who were biopsied 78 
for abnormal urinalysis / raised serum creatinine (SCr) identified during pregnancy 79 
(regardless of the timing of the subsequent biopsy), and all women biopsied within one year 80 
postpartum were included in the pregnancy-related diagnosis group. Repeat and inadequate 81 
biopsies were excluded. Protein: Creatinine Ratio (PCR) was recorded where available, and 82 
quantification in g/24hr was converted to an estimated PCR by multiplying by 100. Albumin: 83 
Creatinine Ratio (ACR) quantification were excluded from analyses as they could not be 84 
reliably converted to an estimated PCR. 85 
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Rate of change of estimated GFR (eGFR) per year was calculated using the CKD-EPI 86 
formula (2).  Women of mixed race that included black heritage were categorised as black. 87 
Women who were on RRT during follow-up were considered to have eGFR of 10ml/min per 88 
1.73m2 for the purpose of calculating change in renal function over time. In view of the 89 
expected physiological fall in serum creatinine (SCr) during pregnancy, for the purpose of 90 
assessing eGFR and rate of change in eGFR, comparison was made between controls and 91 
post-pregnancy patients only i.e. women biopsied during pregnancy were not included in this 92 
analysis due to inaccuracies of GFR estimates in pregnancy (3, 4). 93 
Each biopsy was assigned a primary diagnosis, and additional concurrent diagnoses 94 
recorded. If focal segmental glomerulosclerosis (FSGS) was present but deemed to be 95 
secondary to an alternative intrinsic renal pathology, cases were categorised according to 96 
the primary diagnosis and not FSGS. All pregnancy-related biopsies and all indeterminate 97 
cases (including in the control group) were re-reviewed by two histopathologists 98 
independently with consensus agreement for diagnosis.  All FSGS biopsies (pregnancy-99 
related and controls) were formally classified according to Columbia classification (5). For 100 
the remaining controls, the biopsy diagnosis in the original report was used.  101 
 102 
Statistical Analyses 103 
Control women were matched against pregnant women by age (at last birthday) and ethnic 104 
group (black vs non-black) and unmatched controls dropped. In order to maintain power, all 105 
controls matched for age and ethnicity were included. Proportions were compared using two-106 
sided Chi-Square test with Yate’s correction, and the non-parametric Mann-Whitney U test 107 
was used for non-normally distributed continuous variables. Logistic regression analysis with 108 
a dummy variable for matching group was used to adjust for any effect of age, ethnicity, or 109 
their interaction on diagnosis and renal outcomes. Spearman’s rank correlation was used to 110 
explore the relationship between non-normally distributed continuous variables. Statistical 111 
analyses were performed using Stata version 14.1 (StataCorp, College Station, Texas) and 112 
GraphPad Prism (version 7.0). 113 
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 114 
Results 115 
1399 biopsies were identified in women aged between 16-50 years, including 173 116 
pregnancy-related biopsies (19 antenatal, 154 post-pregnancy) and 1226 control biopsies, 117 
between 1997 and 2012. One thousand control women were matched for age and ethnicity, 118 
and included all women with equal ages and ethnicities as the pregnancy-related group i.e. 119 
women were not excluded if there was more than one match per pregnancy-related case. 120 
Figure 1 shows how the matched cohorts were assembled, and the baseline demographics 121 
are shown in Table 1. The median age of women with a pregnancy-related diagnosis was 122 
significantly lower than controls, and there was a higher proportion of women of ‘black or 123 
black British’ ethnicity in the pregnancy-related group compared to controls. SCr at the time 124 
of biopsy was significantly lower in the pregnancy-related group. There was no difference in 125 
urinary PCR between women with biopsies performed post-pregnancy and controls, but 126 
PCR in women with biopsies performed antenatally was significantly higher than those 127 
performed after delivery (p=0.02), and compared to controls (p=0.02). 128 
 129 
Histological diagnoses  130 
Focal segmental glomerulosclerosis (FSGS) was the primary diagnosis in 32.4% (56/173) of 131 
pregnancy-related biopsies compared to 9.7% (97/1000) of controls (p<0.001). Lupus 132 
nephritis (LN) was found more commonly in controls (23.5% (235/1000) vs 13.9% (24/173), 133 
p=0.001) (Table 2). 134 
Women with pregnancy-related FSGS were younger than controls but there were no 135 
significant differences in ethnicity or Colombia classification between groups.  Creatinine at 136 
time of biopsy was significantly lower in the pregnancy-related group.  (Table 3). There were 137 
no disagreements between histopathologists in diagnoses or Columbia Classifications. 138 
 139 
Renal outcomes 140 
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The date of delivery was available in 67.5% of biopsies performed after delivery. The median 141 
time from delivery to biopsy was 199 days (IQR 92, 312), including nine biopsies performed 142 
within six weeks. Follow-up data on renal function were available for 58.4% (101/173) of the 143 
pregnancy-related group and 45.9% (459/1000) of the control group (Table 3). There was no 144 
difference in the median follow-up time between pregnancy-related and control groups. 145 
Women with a pregnancy-related diagnosis (excluding those diagnosed antenatally), were 146 
more likely to have an overall decline in eGFR in the follow-up period than matched controls 147 
despite adjustment for remaining differences in age and ethnicity between groups (odds ratio 148 
1.67, 95% CI 1.03-2.71, p=0.04). This decline also appeared to be more rapid in the 149 
pregnancy-related group (-1.33 vs -0.56ml/min per 1.73m2 per year respectively; p=0.045). 150 
There was no correlation between age and rate of decline in eGFR (Spearman’s Rho=0.03, 151 
n=546, p=0.53). There were no significant differences between the proportion of women 152 
requiring RRT between pregnancy-related cases and controls or deaths during the follow-up 153 
period (Table 4).  154 
There were no significant differences in rate of change in eGFR in women with FSGS 155 
between groups, or requirement for RRT or death (Table 5). 156 
 157 
Comparison between antenatal and postpartum biopsies 158 
Median SCr was similar, and urinary PCR higher, at the time of biopsy in women biopsied 159 
antenatally compared to those biopsied post-pregnancy (table 1). There were no differences 160 
in biopsy diagnoses between groups (table 2) and no difference in those that died or 161 
required RRT (table 3). 162 
 163 
Discussion 164 
Main findings 165 
This study demonstrates the wide range of glomerular diseases identified by renal biopsy 166 
during or within one year of pregnancy, supporting the role of renal biopsy for confirmation of 167 
diagnosis in this patient group. FSGS was more frequently reported in pregnancy-related 168 
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biopsies than in controls, but no differences in Colombia classification were observed. 169 
Conversely lupus nephritis was less commonly identified during or after pregnancy than in 170 
controls. Women with a pregnancy-related diagnosis had lower SCr concentrations at time of 171 
biopsy than controls, thus pregnancy may provide an opportunity to identify CKD at earlier 172 
stages.  Women with biopsies after pregnancy also had a more rapid decline of eGFR during 173 
follow-up than controls, despite comparable severity of proteinuria, highlighting the 174 
importance of detection and diagnosis of renal disease revealed by pregnancy. Nearly one in 175 
forty women (2.3%) with a pregnancy-related renal biopsy died and one in eight (12.7%) 176 
required RRT during the follow-up period. This emphasises the severity of a diagnosis of 177 
glomerular disease in young women, and the substantial implications it has for the individual 178 
and her new family. 179 
 180 
Strengths and weaknesses 181 
To our knowledge, this is the largest study of pregnancy and post-pregnancy biopsies with 182 
secondary histological classification, and the only study to include controls with matching for 183 
age and ethnicity. Data were from 21 referring centres hence unlikely to be confounded by 184 
centre specific subjective decision making about indications for biopsy.  However, the study 185 
is unable to address the long-term renal outcomes of other renal diseases identified within 186 
one year of pregnancy that do not require biopsy for diagnosis e.g. reflux nephropathy or 187 
cystic kidney disease, thus these data relate only to glomerular disease. One of the 188 
limitations of our study was the absence of detailed pregnancy data (including parity and 189 
diagnosis of pre-eclampsia) hence it was not possible to establish the relationship between 190 
pregnancy outcomes and renal biopsy lesions. Furthermore, due to the large number of 191 
centres included it was not possible to confirm that all control women had not had a recent 192 
pregnancy which was not reported on the biopsy request form. We acknowledge also that 193 
follow-up data on renal function was available for approximately half of the pregnant and 194 
control groups. 195 
 196 
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FSGS 197 
FSGS was found in nearly a third of pregnancy-related biopsies, with no differences in 198 
Columbia classification of FSGS between pregnancy-related and control groups.  FSGS was 199 
also the most common diagnosis in postpartum biopsies by Day et al, identified in a 200 
comparable proportion of pregnancies (28%) but Columbia classification of FSGS was not 201 
reported (6). FSGS lesions (7, 8)  and ‘FSGS-like’ lesions (9) have been described in some 202 
biopsy series of women with pre-eclampsia, with correlation between severity of lesions and 203 
clinical findings (10) . 204 
Unlike animal micropuncture studies (11) which report unchanged intraglomerular pressure 205 
during pregnancy, a recent systematic review, using synthesised estimations from formal 206 
assessment of renal plasma flow and glomerular filtration rate (GFR), described an increase 207 
in filtration fraction in healthy pregnancy (12), thus further exacerbation of haemodynamic 208 
changes could contribute to the development of FSGS in pre-eclampsia.  However, the 209 
proportion of biopsies with the perihilar variant of FSGS, which is the typical pattern of 210 
adaptive FSGS in non-pregnant patients (13), was not greater in pregnancy-related cases 211 
than control groups in our study, although true discrepancies may not have been identified 212 
by the small numbers within classification subgroups. 213 
More recently podocyte loss has been proposed to lead to progressive renal injury in women 214 
with pre-eclampsia.  Podocyturia is reported in women with pre-eclampsia, prior to, at time of 215 
diagnosis and postpartum (14 –16) and downregulation of podocyte-specific proteins (e.g. 216 
nephrin, synaptopodin and GLEPP-1) is reported in the renal biopsies of women with 217 
preeclampsia (17, 18). Similarly, podocyturia is observed in patients with FSGS (19) and 218 
with progression of other glomerular diseases (20). However, there is a regression of 219 
histological findings of pre-eclampsia, including complete resolution of ‘FSGS-like lesions’ 220 
after delivery in historic large biopsy series (10, 21). Furthermore,  detailed renal 221 
physiological assessment of 57 women with pre-eclampsia observed that functional 222 
manifestations of glomerular endothelial injury were undetectable after four weeks (22), 223 
suggesting that immediate pathophysiological changes secondary to pre-eclampsia may not 224 
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be contributory to persistent renal abnormalities in the postpartum period, and that pre-225 
existing renal injury may be important. For example, one in five women with severe pre-226 
eclampsia had underlying renal disease in a biopsy series of 86 women (23) and a wide 227 
range of renal pathologies were reported in a population study of renal biopsies performed in 228 
pregnancies complicated by pre-eclampsia (24). Moreover, Norwegian population studies 229 
have identified pre-eclampsia in a previous pregnancy to be associated with increased 230 
relative risk of having a future renal biopsy (24), and developing future ESRD (25) but the 231 
risk of progression to ESRD in women with renal biopsies remote from pregnancy is not 232 
augmented by a history of previous pre-eclampsia (26) .  233 
 234 
Other histological diagnoses 235 
Higher rates of LN were observed in the renal biopsies of the control group compared to 236 
women in the pregnancy-related group. A recent systematic review reported an estimated 237 
rate of 16.1% (95% CI 9.0-23.2%) lupus nephritis flare during pregnancy (27). However, Day 238 
et al reported LN to be present in 35% and 8% of biopsies performed in pregnancy and 239 
postpartum respectively (6). The lower incidence of LN diagnosed within one year of 240 
pregnancy in this study may reflect more women with SLE conceiving with quiescent disease 241 
or differences in local practice. For example, due to perceived risks of renal biopsy during 242 
pregnancy, some physicians may treat women who develop LN empirically without biopsy.  243 
 244 
Progression of CKD 245 
In this study, women with a pregnancy-related diagnosis had lower SCr at time of biopsy 246 
than  controls, even after exclusion of antenatal biopsies and adjustment for age. Pregnancy 247 
is associated with a 50% increase in glomerular filtration thus is a ‘stress test’ for the kidney 248 
(28) , and may provide an opportunity to detect early disease. Our study also identified a 249 
more rapid decline in GFR in women with renal disease identified within one year of 250 
pregnancy despite comparable levels of proteinuria, less severe disease at diagnosis, and 251 
adjustment for age and ethnicity. The National Institute of Clinical Health Excellence (NICE) 252 
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recommend that the absolute risk of renal disease after hypertensive complications in 253 
pregnancy is low and no specific advice or follow-up is required (29), and there are no 254 
specific recommendations regarding follow-up of renal disease identified during pregnancy. 255 
NICE guidelines recommend that 24-hour urine collection remains the gold standard of 256 
analysis of proteinuria in pregnancy; however spot urine PCR is an acceptable alternative 257 
therefore both methods were included. There is insufficient evidence on the use of ACR in 258 
pregnancy (29, 30) and therefore they were not included in the analysis.  The CKD-EPI 259 
formula may underestimate GFR in pregnant women (2, 31) hence cases with antenatal 260 
biopsies were not included in analyses of renal function. Nine of the postpartum group were 261 
biopsied within six weeks of delivery, and a persistent pregnancy related elevation in eGFR 262 
may have influenced findings, although this effect is likely to be minimal. It is also possible 263 
that nephrology led follow-up of only women with more severe disease diagnosed during or 264 
after pregnancy may confound analysis of progression of renal disease, although the 265 
inclusion of five renal centres in this study reduces the influence of individual centre policy 266 
on selection of women who continued to have nephrological follow-up. The rate of ESRD 267 
(12.7%) in women with a pregnancy-related diagnosis was not higher than controls, but 268 
appears to be lower than a smaller study of 53 women with proteinuria identified in 269 
pregnancy performed over two decades ago (21% progressed to ESRD) (32). In contrast, 270 
Day et al reported much higher rates of women developing ESRD (30%) after women 271 
biopsied antenatally which may reflect differences in thresholds for biopsy or length of follow-272 
up. The high rate of progression of renal disease identified during pregnancy suggests that 273 
earlier intervention and nephrology follow-up, even for those with less severe disease, is 274 
warranted. 275 
 276 
Indications and safety of biopsy  277 
Due to the large number of centres included we were unable to obtain detailed clinical 278 
information following the biopsy which is a limitation of this study.  Thus we are unable to 279 
compare risk of biopsy during or after pregnancy with controls.  The decision to perform a 280 
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renal biopsy during pregnancy is complex for both the clinician and mother. However, our 281 
data and others support the role of renal biopsy either during or after pregnancy as 282 
histological confirmation is likely to lead to a change in management in the majority of 283 
women (33). 284 
 285 
Conclusions 286 
The findings of this study support the use of renal biopsy as a diagnostic tool for the 287 
investigation of renal disease identified during or within one year of pregnancy. Pregnancy 288 
provides an opportunity for detection of disease and thus prevention of CKD progression and 289 
of future cardiovascular disease.  FSGS is more commonly found in women who have been 290 
pregnant than in controls and furthermore, women with a pregnancy-related diagnosis have 291 
a more rapid progression of disease. Further work is required to determine whether 292 
pregnancy initiates, exacerbates or reveals renal disease.  293 
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Table 1. Demographics of women of childbearing age - all diagnoses 404 
 
Controls 
Pregnancy Related 
(Antenatal & 
Post-pregnancy) 
P Value Antenatal Post-pregnancy P Value 
N = 
 
Median Age  
Years (IQR) 
 
 
Ethnicity N (%) 
White 
Mixed 
Asian/Asian British 
Black/Black British 
Other Groups 
Not stated 
1000 
 
34.2 (28.0, 41.0) 
 
 
 
 
324 (32.4) 
12 (1.2) 
141 (14.1) 
133 (13.3) 
97 (9.7) 
293 (29.3) 
173 
 
32.1 (27.8, 36.5) 
 
 
 
 
53 (30.6) 
2 (1.2) 
18 (10.4) 
45 (26.0) 
14 (8.1) 
41 (23.7) 
 
 
 
0.004
a 
 
 
 
 
0.65
a 
0.96
a
 
0.19
a
 
<0.001
a
 
0.50
a
 
0.13
a
 
 
19 
 
30.9 (25.5, 36.0) 
 
 
 
 
8 (42.1) 
0 (0.0) 
1 (5.3) 
7 (36.8) 
2 (10.5) 
1 (5.3) 
154 
 
32.2 (28.4, 36.9) 
 
 
 
 
45 (29.2) 
2 (1.3) 
17 (11.0) 
38 (24.7) 
12 (7.8) 
40 (26.0) 
 
 
0.25
b 
 
 
 
 
0.29
b
 
>0.99
b
 
0.70
b
 
0.27
b
 
0.65
b
 
0.05
b
 
N = 
 
Median SCr at time of 
biopsy  
mg/dl (IQR) 
 
Median CKD-EPI GFR at 
time of biopsy 
ml/min per 1.73m
2 
(IQR) 
 
825 
 
1.11 (0.77, 2.06) 
 
 
 
65.9 (30.8, 102.6) 
 
 
152 
 
0.90 (0.74, 1.51) 
 
 
 
85.7 (47.6, 114.1) 
 16 
 
0.79 (0.63, 1.33) 
 
 
 
108.2 (60.4, 130.2) 
 
 
136 
 
0.90 (0.74, 1.58) 
 
 
 
84.1 (46.8 (112.3) 
 
 
 
 
0.18
b
, 0.002
c 
 
 
 
<0.001
c 
 
 
N =  
 
Median Urine PCR at 
time of biopsy  
mg/mmol (IQR) 
 
609 
 
240.0 (100.0, 576.0) 
 
 
131 
 
237.0 (125.0, 580.0) 
 
 
 
 14 
 
536.5 (280.3, 824.5) 
 
117 
 
200.0 (121.0, 503.5) 
 
 
 
 
0.02
b
, 0.80
c
 
 
SCr = Serum Creatinine, PCR = Protein: Creatinine Ratio, IQR = interquartile range, 
a
comparison between Controls and Pregnancy-Related 405 
(Antenatal & Post-pregnancy), 
b
comparison between Antenatal and Post-pregnancy, 
c
comparison between Controls and Post-pregnancy. 406 
17 
 
Table 2. Renal biopsy diagnoses in women of childbearing age comparing disease identified in pregnancy with controls 407 
 
Controls 
Pregnancy 
Related 
(Antenatal & 
Post-
pregnancy) 
P Value
a
 
 
Adjusted for Age & Ethnicity 
(95% CI)
a
 
Antenatal 
Post-
pregnancy 
P Value
b
 
OR (95% CI) 
P 
Value 
N = 1000 173    19 154 
 
FSGS N (%) 97 (9.7) 
 
56 (32.4) 
 
<0.001 4.42 (3.00 to 6.55) <0.001 6 (31.6) 104 (32.5) >0.99 
Lupus N (%) 235 (23.5) 
 
24 (13.9) 
 
0.005 0.44 (0.28 to 0.70) 0.001 5 (26.3) 19 (12.3) 0.15 
IgA N (%) 147 (14.7) 
 
25 (14.5) 
 
0.93 1.10 (0.69 to 1.76) 0.69 1 (5.3) 24 (15.6) 0.32 
Interstitial Nephritis N (%) 62 (6.2) 
 
8 (4.6) 
 
0.42 0.74 (0.35 to 1.59) 0.45 0 (0.0) 8 (5.2) 0.60 
Membranous N (%) 53 (5.3) 
 
9 (5.2) 
 
0.96 1.01 (0.48 to 2.10) 0.99 2 (10.5) 7 (4.5) 0.26 
Minimal Change N (%) 50 (5.0) 
 
5 (2.9) 
 
0.23 0.59 (0.23 to 1.51) 0.27 0 (0.0) 5 (3.2) >0.99 
Thin Membrane N (%) 30 (3.0) 
 
9 (5.2) 
 
0.14  2.11 (0.97 to 4.60) 0.06 0 (0.0) 9 (5.8) 0.60 
DM N (%) 35 (3.5) 
 
1 (0.6) 
 
0.04 0.18 (0.25 to 1.42) 0.10 0 (0.0) 1 (0.7) >0.99 
Crescentic N (%) 14 (1.4) 
 
0 (0.0) 
 
0.12 1.0 (-) - 0 (0.0) 0 (0.0) >0.99 
FSGS (HIV) N (%) 6 (0.6) 
 
1 (0.6) 
 
0.97 0.51 (0.06 to 4.37) 0.54 0 (0.0) 1 (0.6) >0.99 
Other N (%) 271 (27.1) 
 
35 (20.2) 
 
0.06 0.73 (0.50 to 1.08) 0.12 5 (26.3) 30 (19.5) 0.54 
OR = Odds Ratio, CI = Confidence Interval, 
a
comparison between Controls and Pregnancy-Related (Antenatal & Post-pregnancy), 
b
comparison 408 
between Antenatal and Post-pregnancy, - logistic regression failed. 409 
 410 
 411 
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Table 3. Demographics of women of childbearing age with FSGS 412 
 Controls 
Pregnancy Related 
(Antenatal & Post-
pregnancy) 
P Value Antenatal Post-pregnancy P Value 
N = 
 
Median Age Years (IQR) 
 
Ethnicity N (%) 
White 
Mixed 
Asian/AsianBritish 
Black/Black British 
Other Groups 
Not stated 
 
Columbia Classification 
N (%) 
Cellular 
Collapsing 
NOS 
Perihilar 
Tip 
Not Classified 
 
97 
 
35.7 (30.3, 41.9) 
 
 
29 (29.9) 
1 (1.0) 
10 (10.3) 
22 (22.7) 
9 (9.3) 
26 (26.8) 
 
 
 
3 (3.1) 
7 (7.2) 
67 (69.1) 
8 (8.2) 
8 (8.2) 
4 (4.1) 
56 
 
33.4 (27.3, 39.1) 
 
 
18 (32.1) 
1 (1.8) 
4 (7.1) 
18 (32.1) 
2 (3.8) 
13 (23.2) 
 
 
 
3 (5.4) 
1 (1.8) 
38 (67.9) 
8 (14.3) 
6 (10.7) 
0 (0.0) 
 
 
 
0.05
a 
 
 
0.77
a
 
0.69
a
 
0.51
a
 
0.20
a
 
0.19
a
 
0.62
a
 
 
 
 
0.49
a
 
0.15
a
 
0.88
a
 
0.24
a
 
0.61
a
 
0.12
a
 
 
6 
 
29.5 (22.5, 37.1) 
 
 
3 (50.0) 
0 (0.0) 
0 (0.0) 
3 (50.0) 
0 (0.0) 
0 (0.0) 
 
 
 
1 (16.7) 
0 (0.0) 
5 (83.3) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
 
50 
 
33.7 (28.7, 39.2) 
 
 
15 (30.0) 
1 (2.0) 
4 (8.0) 
15 (30.0) 
2 (4.0) 
13 (26.0) 
 
 
 
2 (4.0) 
1 (2.0) 
33 (66.0) 
8 (16.0) 
6 (12.0) 
0 (0.0) 
 
 
0.26
b 
 
 
0.38
b
 
>0.99
b
 
>0.99
b
 
0.37
b
 
>0.99
b
 
0.32
b
 
 
 
 
0.29
b
 
>0.99
b
 
0.65
b
 
0.58
b
 
>0.99
b
 
>0.99
b
 
 
N = 
 
Median SCr at time of 
biopsy mg/dl (IQR) 
 
Median CKD-EPI GFR at 
time of biopsy  
ml/min per 1.73m
2 
(IQR) 
 
79 
 
1.07 (0.84, 1.75)  
 
 
 
71.6 (41.2, 92.6) 
 
49 
 
0.92 (0.72,1.32)  
 
 
 
86.0 (58.3, 112.0) 
 5 
 
0.92 (0.64, 1.48)  
 
 
 
102.1 (49.5, 135.7) 
 
44 
 
0.93 (0.75, 1.29) 
 
 
 
85.4 (58.4, 110.2) 
 
 
 
 
0.85
b
,0.04
c 
 
 
 
0.02
c 
 
 
N =  
 
Median Urine PCR at 
time of biopsy mg/mmol 
(IQR) 
72 
 
340.0 (165.0, 629.5) 
 
 
43 
 
237.0 (160.0, 600.0) 
 
 5 
 
600.0 (250.0, 708.0) 
 
38 
 
200.0 (157.5, 495.3) 
 
 
 
0.17
b
, 0.27
c 
SCr = Serum Creatinine, PCR = Protein: Creatinine Ratio, IQR = interquartile range, 
a
comparison between Controls and Pregnancy-Related 413 
(Antenatal & Post-pregnancy), 
b
comparison between Antenatal and Post-pregnancy, 
c
comparison between Controls and Post-pregnancy. 414 
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Table 4. Follow-up of women of childbearing age - all diagnoses 415 
 
Controls 
Pregnancy 
Related 
(Antenatal & 
Post-pregnancy) 
P Value Antenatal Post-pregnancy P Value 
N = 
 
Median Follow-
up Time 
Months (IQR) 
 
Median Rate of 
Change in CKD-
EPI GFR 
ml/min per 
1.73m
2 
per year 
(IQR) 
 
459 
 
44.3 (20.1, 77.2) 
 
  
 
-0.56 (-4.26, 3.22) 
 
 
 
 
 
101 
 
42.8 (17.4, 70.9)  
 
 
 
-2.43 (-8.16, 0.18) 
 
 
 
 
 
 
0.48
a 
 
14 
 
40.8 (24.2, 75.6)  
 
 
 
-7.36 (-15.44, -4.35) 
 
 
 
87 
 
43.3 (17.0, 70.8)  
 
 
 
-1.33 (-6.97, 0.94) 
 
 
 
 
 
 
>0.99
b 
 
 
 
0.002
b
,
 
0.045
c 
 
 
 
 
 
 
Died % (N) 
 
RRT % (N) 
 
Time to reach 
RRT Months 
(IQR) 
 
Age at RRT 
Years (IQR) 
 
 
3.4 (34/1000) 
 
13.0 (130/1000) 
 
18.55 (5.37, 45.79) 
 
 
 
37.9 (30.4, 44.1) 
 
 
2.3 (4/173) 
 
12.7 (22/173) 
 
17.8 (7.3, 46.5) 
 
 
 
34.0 (27.7, 40.8) 
 
 
0.46
a 
 
0.92
a 
 
0.93
a 
 
 
 
0.27
a 
 
 
(10.5) 2/19 
 
15.8 (3/19) 
 
17.8 (11.3, 89.5) 
 
 
 
34.2 (24.9, 40.3) 
 
 
 
1.3 (2/154) 
 
12.3 (19/154) 
 
19.8 (4.5, 44.7) 
 
 
 
33.2 (27.7, 42.2) 
 
0.06
b 
 
0.72
b 
 
0.53
b 
 
 
 
0.74
b 
RRT = Renal Replacement Therapy, CKD = Chronic Kidney Disease, IQR = interquartile range, 
a
comparison between Controls and Pregnancy-416 
Related (Antenatal & Post-pregnancy), 
b
comparison between Antenatal and Post-pregnancy, 
c
comparison between Controls and Post-pregnancy. 417 
 418 
 419 
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Table 5. Follow-up in women of childbearing age with FSGS 420 
 Controls Pregnancy Related 
(Antenatal & Post-
pregnancy) 
P Value Antenatal Post-pregnancy P Value 
N =  
 
Median Follow-
up Time 
Months (IQR) 
 
 
Median Rate of 
Change in CKD-
EPI GFR 
ml/min per 
1.73m
2 
per year 
(IQR) 
 
49 
 
45.9 (26.3, 92.6) 
 
 
 
 
-1.98 (-5.98, 0.26) 
 
 
 
31 
 
48.0 (30.6, 75.9) 
 
 
 
 
-2.66 (-8.97, 0.00) 
 
 
 
0.83
a 
 
4 
 
41.9 (37.0, 78.3) 
 
 
 
 
-8.48 (-12.85, -6.89) 
 
 
27 
 
50.3 (20.0, 75.9) 
 
 
 
 
-1.62 (-7.55, 0.21) 
 
 
>0.99
b 
 
 
 
 
0.06
b
, 0.91
c 
 
 
 
 
Died % 
 
RRT % 
 
Time to reach 
RRT Months 
(IQR) 
 
Age at RRT 
Years (IQR) 
 
 
3.1 (3/97) 
 
15.5 (15/97) 
 
46.0 (12.99, 68.13) 
 
 
 
39.3 (33.4,46.6) 
 
 
 
1.8 (1/56) 
 
7.1 (4/56) 
 
64.7 (50.3, 89.5) 
 
 
 
40.3 (32.1, 40.3) 
 
 
0.63
a 
 
0.13
a 
 
0.17
a 
 
 
 
0.77
a 
 
 
16.7 (1/6) 
 
16.7 (1/6) 
 
89.5 
 
 
 
40.3 
 
0.0 (0/50) 
 
6.0 (3/50) 
 
57.5 (50.3, 64.7) 
 
 
 
36.2 (32.1, 40.3) 
 
0.11
b 
 
0.37
b 
 
- 
 
 
 
- 
RRT = Renal Replacement Therapy, CKD = Chronic Kidney Disease, IQR = interquartile range, 
a
comparison between Controls and Pregnancy-421 
Related (Antenatal & Post-pregnancy), 
b
comparison between Antenatal and Post-pregnancy, 
c
comparison between Controls and Post-pregnancy. 422 
 423 
 424 
 425 
 426 
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Figure 1. Identification and assembly of matched cohorts 427 
